3D细胞培养市场－全球产业规模、份额、趋势、机会及预测（依技术、应用、最终用途、地区及竞争格局划分，2021-2031年）

全球 3D 细胞培养市场预计将从 2025 年的 117.8 亿美元成长到 2031 年的 186.4 亿美元，复合年增长率为 7.95%。

该市场涵盖了能够使细胞在三维环境中生长的技术，这种环境比标准的单层培养技术更能精确地模拟体内环境。其成长主要受以下因素驱动：药物研发领域对动物模型替代测试方法的需求日益增长，以及对个人化医疗的日益重视。此外，慢性疾病的增加也催生了再生医学和肿瘤学领域对可靠疾病模型的需求。例如，美国癌症协会预测，到2024年，美国将新增2,001,140例癌症病例，这将推动业界对精准的体外肿瘤模型的需求，以加速治疗方法的研发。

儘管成长势头强劲，但由于各种3D培养平台缺乏标准化和可重复性，市场仍面临许多挑战。建构均一​​的支架基质和维持一致的微环境涉及许多复杂环节，往往导致实验数据出现差异，并使监管核准所需的检验步骤更加复杂。因此，实施这些复杂系统的高昂成本以及对专业技术知识的需求，仍然是限制其在小规模实验室和商业机构中广泛应用的重要障碍。

市场驱动因素

药物研发中3D细胞培养模型的广泛应用，其根本驱动力在于伦理和监管方面的迫切需求，即以更具预测性和更贴近人体实际情况的系统取代动物实验。药物研发人员正优先考虑生理上精确的人源类器官，以更好地预测药物的毒性和疗效，从而摒弃传统的单层细胞培养方法，因为后者往往无法重现复杂的生物反应。联邦政府大力推动新型方法的标准化，使其适用于工业应用，也为此趋势提供了支持。值得注意的是，Fierce Biotech在2025年9月报道称，美国国立卫生研究院（NIH）已授予一项价值8700万美元的合同，用于建立一个“标准化类器官建模中心”，旨在减少转化科学中对动物模型的依赖。这种高水准的支持将透过最大限度地降低物种间差异带来的风险，促进3D平台的商业性化应用。

与监管政策的调整同步，微流体和生物列印等先进技术的进步，使得建构复杂的功能性组织系统成为可能，并推动市场发展。器官晶片介面和血管化技术的创新，有助于解决厚组织构建体中营养输送的难题，并吸引了大量研发资金。例如，2025年10月，博伊西州立大学新闻报道称，研究人员获得了200万美元的津贴，用于开发适用于3D生物打印组织的可适应、柔性电子界面，以推进“类器官智能”的发展，这凸显了工程学和生物学的融合。鑑于药物研发涉及巨大的财务风险，这种技术成熟至关重要。 BioSpace在2025年5月指出，2024年全球药物研发支出将达到约2,880亿美元，增加了开发高效3D培养工具的压力，以将这些巨额投资转化为治疗成果。

市场挑战

不同3D细胞培养平台缺乏标准化和可重复性，严重阻碍了全球3D细胞培养市场的成长。由于这些系统通常依赖复杂的微环境和精密的支架基质，不同实验室甚至不同批次的实验数据可能有显着差异。这种不一致增加了监管机构检验流程的难度，因为监管机构需要严格且可重复的证据来确保新型疗法的安全性。因此，製药公司往往不愿意将这些技术全面整合到其关键的药物开发平臺中，担心数据差异会导致代价高昂的延误和监管部门的拒绝。

由于性能和可靠性方面存在不确定性，业界采取了谨慎的态度，导致商业性化应用速度放缓。此类整合相关的财务风险庞大，进一步阻碍了非标准化工具的使用。根据美国药品研究与製造商协会 (PhRMA) 2024 年的报告，其成员公司在过去十年中已在研发活动方面投入超过 8,500 亿美元。鑑于如此庞大的投资，业界需要能够确保结果一致性的调查方法，而目前缺乏标准化是市场扩张的直接障碍。

市场趋势

高通量筛检自动化技术的整合正在迅速改变市场格局，它消除了传统上复杂3D模型维护所需的大量人工环节。自动化液体处理和培养系统能够精确控制精细的球状体和类器官的工作流程，从而在不影响细胞活性的前提下实现生理检测的规模化。这种操作方式的转变对于3D生物学的产业化至关重要，它以标准化的通讯协定操作流程取代了人工干预，确保了实验的一致性。这些效率的提升意义重大：根据Molecular Devices公司（2025年8月）报道，其推出的专用摇床培养技术将脑类器官培养所需的人工操作时间减少了90%，显着加快了神经退化性疾病研究的进程。

同时，人工智慧与3D影像分析的融合对于解读多细胞模型产生的庞大且复杂的资料集至关重要。先进的机器学习演算法正被应用于解读晶片器官和组织构建体中复杂的形态模式，并识别传统分析方法无法检测到的细微表型​​反应。计算智能与人性化的生物学之间的这种协同作用，正显着推动资本流向能够更准确预测临床结果的平台。这一趋势在2025年1月尤为明显，当时Valo Health宣布扩大与诺和诺德的合作。这项旨在利用人工智慧驱动的人体组织模型发现新型疗法的合作，涉及高达46亿美元的里程碑付款。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球3D细胞培养市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（基于支架的、无支架的、生物反应器、微流体、生物列印）
  • 按应用领域（癌症研究、干细胞研究/组织工程、药物开发/毒性测试）
  • 依最终用户（生技/製药公司、学术/研究机构、医院、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美3D细胞培养市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲3D细胞培养市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区3D细胞培养市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲3D细胞培养市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲3D细胞培养市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球3D细胞培养市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Tecan Trading AG
• Merck KGaA
• Promocell GmbH
• Lonza Group
• Tecan Trading AG
• CN Bio Innovations Ltd.
• TissUse GmbH
• Cellendes GmbH
• Greiner Bio-one International GmbH
• Advanced BioMatrix, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global 3D Cell Culture Market is projected to expand from USD 11.78 Billion in 2025 to USD 18.64 Billion by 2031, exhibiting a CAGR of 7.95%. This market encompasses technologies that enable cells to proliferate in a three-dimensional setting, mimicking natural in vivo conditions more accurately than standard monolayer techniques. Growth is primarily fuelled by the rising demand for alternative testing methods to supersede animal models in pharmaceutical research and an increasing emphasis on personalized medicine. Furthermore, the growing prevalence of chronic diseases requires robust disease modeling for regenerative medicine and oncology; for instance, the American Cancer Society projected 2,001,140 new cancer cases in the United States in 2024, intensifying the industrial need for precise in vitro oncology models to expedite therapeutic development.

Despite this positive growth trajectory, the market encounters significant obstacles regarding the lack of standardization and reproducibility across various 3D culture platforms. The complexity involved in creating uniform scaffold matrices and sustaining consistent microenvironments often results in variable experimental data, complicating the validation steps necessary for regulatory approval. Consequently, the substantial costs linked to deploying these intricate systems, coupled with the need for specialized technical expertise, continue to act as major barriers that limit widespread adoption within smaller research laboratories and commercial organizations.

Market Driver

The increasing utilization of 3D cell culture models in drug discovery is fundamentally driven by urgent ethical and regulatory mandates to replace animal testing with more predictive, human-relevant systems. Pharmaceutical developers are prioritising physiologically accurate human-derived organoids to improve the prediction of toxicity and efficacy, shifting away from conventional monolayer cultures that often fail to replicate complex biological responses. This movement is bolstered by significant federal efforts to standardize these new methods for industry use; notably, Fierce Biotech reported in September 2025 that the NIH awarded $87 million in contracts to establish the Standardized Organoid Modeling Center, specifically aiming to reduce reliance on animal models in translational science. Such high-level endorsement promotes broader commercial adoption of 3D platforms to minimize risks linked to interspecies variability.

Parallel to regulatory shifts, the market is propelled by sophisticated technological advancements in microfluidics and bioprinting that facilitate the creation of complex, functional tissue systems. Innovations in organ-on-chip interfaces and vascularization are resolving previous limitations regarding nutrient delivery in thick tissue constructs, thereby attracting substantial developmental capital. For example, Boise State News reported in October 2025 that researchers received a $2 million grant to advance "organoid intelligence" by developing flexible electronic interfaces adaptable to 3D bioprinted tissues, highlighting the convergence of engineering and biology. This technical maturation is critical given the immense financial stakes in drug development; BioSpace noted in May 2025 that global pharmaceutical R&D spending reached nearly $288 billion in 2024, increasing the pressure to adopt efficient 3D culture tools that ensure these vast investments yield successful therapeutic outcomes.

Market Challenge

The absence of standardization and reproducibility across varying 3D culture platforms constitutes a significant barrier hampering the growth of the Global 3D Cell Culture Market. Because these systems often rely on intricate microenvironments and complex scaffold matrices, experimental data can fluctuate substantially between different laboratories or even production batches. This inconsistency complicates the validation process required by regulatory bodies, which mandate rigorous and reproducible evidence to ensure the safety of new therapeutics. Consequently, pharmaceutical companies often hesitate to fully integrate these technologies into their critical drug development pipelines, fearing that data variability could lead to costly delays or regulatory rejections.

This uncertainty regarding performance and reliability forces the industry to maintain a cautious approach, thereby slowing widespread commercial adoption. The financial stakes associated with such integration are massive, further discouraging the use of non-standardized tools. According to the Pharmaceutical Research and Manufacturers of America, in 2024, it was reported that member companies had invested over $850 billion in research and development activities over the past decade. Given this immense level of capital commitment, the industry requires testing methodologies that guarantee uniform results, making the current lack of standardization a direct impediment to market expansion.

Market Trends

The integration of High-Throughput Screening Automation is rapidly transforming the market by resolving the bottleneck of labor-intensive maintenance traditionally required for complex 3D models. Automated liquid handling and incubation systems are now capable of managing the delicate workflows of spheroids and organoids with precision, enabling laboratories to scale physiological assays without compromising viability. This operational shift is critical for industrializing 3D biology, as it replaces manual interventions with standardized robotic protocols that ensure experimental consistency. The impact of these efficiencies is profound; according to Molecular Devices, August 2025, the introduction of their specialized rocking incubation technology has reduced the hands-on time required for maintaining brain organoid cultures by 90%, significantly accelerating the timeline for neurodegenerative disease research.

Simultaneously, the Convergence of Artificial Intelligence with 3D Image Analysis is becoming essential for interpreting the massive, complex datasets generated by multi-cellular models. Advanced machine learning algorithms are now deployed to deconvolute intricate morphological patterns within organ-on-chip and tissue constructs, identifying subtle phenotypic responses that traditional analysis methods fail to detect. This synergy between computational intelligence and human-centric biology is driving substantial capital allocation toward platforms that can predict clinical outcomes more accurately. This trend was exemplified when Valo Health, January 2025, announced an expanded collaboration with Novo Nordisk to discover novel therapeutics using AI-driven human tissue models, a partnership valued at up to $4.6 billion in potential milestone payments.

Key Market Players

• Tecan Trading AG
• Merck KGaA
• Promocell GmbH
• Lonza Group
• Tecan Trading AG
• CN Bio Innovations Ltd.
• TissUse GmbH
• Cellendes GmbH
• Greiner Bio-one International GmbH
• Advanced BioMatrix, Inc.

Report Scope

In this report, the Global 3d Cell Culture Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

3d Cell Culture Market, By Technology

• Scaffold Based
• Scaffold Free
• Bioreactors
• Microfluidic
• Bioprinting

3d Cell Culture Market, By Application

• Cancer Research
• Stem Cell Research & Tissue Engineering
• Drug Development & Toxicity Testing

3d Cell Culture Market, By End-Use

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes
• Hospitals
• Others

3d Cell Culture Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global 3d Cell Culture Market.

Available Customizations:

Global 3d Cell Culture Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global 3d Cell Culture Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Scaffold Based, Scaffold Free, Bioreactors, Microfluidic, Bioprinting)
  • 5.2.2. By Application (Cancer Research, Stem Cell Research & Tissue Engineering, Drug Development & Toxicity Testing)
  • 5.2.3. By End-Use (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America 3d Cell Culture Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By End-Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States 3d Cell Culture Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Canada 3d Cell Culture Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Mexico 3d Cell Culture Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-Use

7. Europe 3d Cell Culture Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By End-Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany 3d Cell Culture Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-Use
  • 7.3.2. France 3d Cell Culture Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom 3d Cell Culture Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy 3d Cell Culture Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain 3d Cell Culture Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-Use

8. Asia Pacific 3d Cell Culture Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By End-Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China 3d Cell Culture Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India 3d Cell Culture Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-Use
  • 8.3.3. Japan 3d Cell Culture Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-Use
  • 8.3.4. South Korea 3d Cell Culture Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia 3d Cell Culture Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-Use

9. Middle East & Africa 3d Cell Culture Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By End-Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia 3d Cell Culture Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-Use
  • 9.3.2. UAE 3d Cell Culture Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-Use
  • 9.3.3. South Africa 3d Cell Culture Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-Use

10. South America 3d Cell Culture Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By End-Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil 3d Cell Culture Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Colombia 3d Cell Culture Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-Use
  • 10.3.3. Argentina 3d Cell Culture Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global 3d Cell Culture Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Tecan Trading AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Promocell GmbH
• 15.4. Lonza Group
• 15.5. Tecan Trading AG
• 15.6. CN Bio Innovations Ltd.
• 15.7. TissUse GmbH
• 15.8. Cellendes GmbH
• 15.9. Greiner Bio-one International GmbH
• 15.10. Advanced BioMatrix, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer